Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis

Dalfampridine sustained-release (SR) is a time-release formulation of 4-aminopyridine, recently approved by the Food and Drug Administration to improve walking in patients with multiple sclerosis (MS). In Phase II trials, walking speed and lower extremity muscle strength was increased in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeffery, Douglas R, Pharr, Emily Poole
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065554/
https://www.ncbi.nlm.nih.gov/pubmed/21468366
http://dx.doi.org/10.2147/CE.S9046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065554/
https://www.ncbi.nlm.nih.gov/pubmed/21468366
http://dx.doi.org/10.2147/CE.S9046

Ejemplares similares